Literature DB >> 33417231

Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices.

Marta Bodro1, Marta Hernández-Meneses1, Juan Ambrosioni2, Laura Linares1, Asunción Moreno1, Elena Sandoval3, Pol Olivas4, María Hernández-Tejero4, José M Miró1, Francesc Marco5, Alex Soriano1.   

Abstract

INTRODUCTION: The objective of this study was to describe two challenging cases of intravascular foreign body infections caused by multidrug-resistant Gram-negative pathogens requiring complex antimicrobial regimens including cefiderocol and successfully treated without implant removal.
METHODS: Clinical charts and microbiological reports of the clinical cases.
RESULTS: Case 1 included a left ventricular assist device (HEARTMATE 3™Abbot®) infection due to Achromobacter xylosoxidans, while case 2 included a portal prosthesis infection due to Pseudomonas aeruginosa. As the pathogens were multidrug-resistant (MDR), both cases required antimicrobial regimens with cefiderocol; treatment was successful without implant removal. Importantly, case 1 presented a probable, drug-induced thrombocytopenia, a non-previously described side effect related to cefiderocol.
CONCLUSION: Cefiderocol may be an additional, promising drug to the available arsenal, even for challenging foreign body infections caused by MDR Gram-negative pathogens.

Entities:  

Keywords:  Cefiderocol; Foreign body infections; Gram-negative bacteria; Multidrug resistance

Year:  2021        PMID: 33417231     DOI: 10.1007/s40121-020-00385-4

Source DB:  PubMed          Journal:  Infect Dis Ther        ISSN: 2193-6382


  3 in total

Review 1.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Authors:  George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

2.  Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Authors:  Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

  3 in total
  3 in total

Review 1.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 2.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 3.  Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.

Authors:  Pasquale Sansone; Luca Gregorio Giaccari; Francesco Coppolino; Caterina Aurilio; Alfonso Barbarisi; Maria Beatrice Passavanti; Vincenzo Pota; Maria Caterina Pace
Journal:  Antibiotics (Basel)       Date:  2022-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.